Company intelligence / Profile preview

Idevax

Antwerp, Antwerp Province, Belgiumidevax.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Idevax’s VAX-ID® is a CE-marked, patented device platform designed to enable accurate and user-independent intradermal drug delivery. The technology is intended to improve vaccine dose-sparing efficiency and patient comfort. As of mid 2025, the product is available for investigational/research use with commercial launch pending regulatory approvals.

Therapeutic areas
ImmunologyRare DiseasesInfectious Diseases
Modalities
Drug delivery devices for intradermal injection
Industry
Therapeutic Medical Devices
02

Drug pipeline

2 assets

VAX-ID

Pre-clinical
Indications
Drug delivery, Vaccination

1 more asset in the full pipeline.

Request access →
03

Partnerships

University of Antwerp / Institute for Vaccines and Infectious DiseasesVoxdaleCollaborations with major pharma/life sciences companies on innovative medical device solutions

Beyond the preview

Go deeper on Idevax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idevax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call